Pre-market · Regular session opens 9:30 AM ET
Last update: Nov 18, 2026, 6:18 PM ET
Merck & Co., Inc.
$137.78▼ 3.90% today
Pre-market

Why Merck & Co., Inc. (MRK) stock moved

Latest session▼ 3.9% · Nov 18, 2026 close

Why Merck & Co., Inc. (MRK) fell 3.9% on November 18, 2026

Merck & Co., Inc. (MRK) fell 3.9% on November 18, 2026, closing at $137.78 versus $143.37 the prior session (close-to-close, from daily closes). Merck disclosed discontinuation of nemtabrutinib (MK-1026), an oral BTK inhibitor and centerpiece of its $2.7 billion ArQule acquisition, after an independent Data Monitoring Committee determined risks outweighed benefits in the Phase 3 BELLWAVE-011 trial for blood cancers. The decision to shut down the entire BELLWAVE program, combined with significant insider selling by EVP Richard Deluca (58,185 shares, ~34% stake reduction), drove the stock down 2.33% to $140.03. Source: Business Wire.

Updated
Prior close
$143.37
Nov 18, 2026 close
$137.78
Change (close-to-close)
−$5.59
−3.90%
As first detected · Nov 18, 2026, 10:32 AM ET

Merck disclosed discontinuation of nemtabrutinib (MK-1026), an oral BTK inhibitor and centerpiece of its $2.7 billion ArQule acquisition, after an independent Data Monitoring Committee determined risks outweighed benefits in the Phase 3 BELLWAVE-011 trial for blood cancers. The decision to shut down the entire BELLWAVE program, combined with significant insider selling by EVP Richard Deluca (58,185 shares, ~34% stake reduction), drove the stock down 2.33% to $140.03. The decline also coincided with the stock falling below its 50-day moving average.

What to watch next: Merck earnings on February 2, 2027 (consensus EPS: $1.78); analyst commentary on pipeline reprioritzation and outlook for other oncology programs.

Source: Business Wire · percentages in this note are as captured at detection; the confirmed close-to-close move is shown above.

Earlier sessions that moved MRK

  1. +3.9%Following its October 29 Q3 beat (revenue $18.09B, up 5% YoY) and raised full-year 2026 guidance, compounded by a $50 million equity investment in Personalis and an expanded Moderna collaboration on individualized neoantigen therapy (V940/mRNA-4157), per web sources.
  2. +3.8%Merck reported third-quarter earnings that topped analyst estimates and raised full-year adjusted profit guidance, driven by stronger-than-expected sales from Keytruda—including its newer injectable form Qlex—and growth from Winrevair (per CNBC, WSJ).
  3. −3.2%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
  4. +3.8%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
  5. −3.3%As profit-taking pressures persist following a multi-month rally that had lifted the stock near $150 in late September.

Merck & Co., Inc. (MRK) shares fell 3.9% to $137.78 as of November 19, 2026, a moderate decline from the prior close of $143.37. BestStocks flagged the session as a major change for MRK. The move is tied to company news. Below, we break down what changed for MRK, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

Company News

MRK fell 3.9% in its latest session, moving from $143.37 to $137.78.

NewsSector-Wide MoveLow confidence
Rel. volume
1.0×
Below Avg
Vs peers
Top 6 of 7 peers
Underperforming
Market cap
$339.7B
New York Stock Exchange
Analyst target
$159
+15.7% vs price
Price chart
Oct 19 – Nov 19
VNNNNFVNNVVEN$138$144$151Oct 19Oct 27Nov 4Nov 11Nov 19
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Merck & Co., Inc. investors

For Merck & Co., Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum; Merck reported third-quarter earnings that topped analyst estimates and raised full-year adjusted profit guidance, driven by stronger-than-expected sales from Keytruda—including its newer injectable form Qlex—and growth from Winrevair (per CNBC, WSJ). Weighing against that: Negative session, down 3.9%; Merck shares fell 2.16% to $141.19 as profit-taking pressures persist following a multi-month rally that had lifted the stock near $150 in late September. Because peers moved similarly, the shift looks more macro- or sector-driven than a change in MRK's fundamentals. Wall Street's consensus price target sits at $159.45, implying +15.7% upside from $137.78. BestStocks rates the overall signal quality low (53/100). With earnings roughly 75 days out, the next report is the most likely near-term test of the move.

MRK price reaction

MRK last traded at $137.78, down $5.59 (-3.90%) from the previous close of $143.37. The session traded on 1.0× average volume (below avg), so participation was unremarkable. Its healthcare peer group moved a median -2.3% over the same stretch, leaving MRK behind the group by 1.6 points. Over the past month the stock has ranged between $137.78 and $150.36, and it currently sits about 0% of the way up that band.

Bullish and bearish analyst opinions on Merck & Co., Inc. (MRK)

The consensus analyst price target on Merck & Co., Inc. (MRK) is $159.45, 15.7% above the recent $137.78. Over the past 90 days analysts logged 0 upgrades, 19 maintains, and 0 downgrades. Here is how the bullish and bearish cases on MRK line up.

The bullish case

  • Wall Street's consensus price target of $159.45 implies +15.7% upside from $137.78.
  • The Street's most bullish target is $180.00 (+30.6%).
  • Positive price momentum.
  • Merck reported third-quarter earnings that topped analyst estimates and raised full-year adjusted profit guidance, driven by stronger-than-expected sales from Keytruda—including its newer injectable form Qlex—and growth from Winrevair (per CNBC, WSJ).
  • Merck surged +12.35% to $151.87 after announcing positive Phase 3 trial results for its personalized mRNA melanoma vaccine (INTerpath-001) developed with Moderna, per web sources.

The bearish case

  • The most bearish analyst target is $105.00 (-23.8%).
  • Negative session, down 3.9%.
  • Merck shares fell 2.16% to $141.19 as profit-taking pressures persist following a multi-month rally that had lifted the stock near $150 in late September.
Bull vs bear balanceBearish Shift
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Nov 19, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $159+15.7%
= 19 maintains
Cantor Fitzgerald maintained Neutral · 2026-11-02
SEC filings watch
8-K2026-11-18
Material event — review for impact
high
10-Q2026-11-04
Quarterly financial results
medium
8-K2026-10-29
Material event — review for impact
high
8-K2026-10-13
Material event — review for impact
high
Peer context
MRK-3.9%
LLY-2.3%
UNH-10.2%
JNJ-2.2%
PFE-1.4%
ABBV-2.3%

Previous notable changes for MRK

Valuation2026-11-18-3.9%via Business Wire ↗
Merck disclosed discontinuation of nemtabrutinib (MK-1026), an oral BTK inhibitor and centerpiece of its $2.7 billion ArQule acquisition, after an independent Data Monitoring Committee determined risks outweighed benefits in the Phase 3 BELLWAVE-011 trial for blood cancers. The decision to shut down the entire BELLWAVE program, combined with significant insider selling by EVP Richard Deluca (58,185 shares, ~34% stake reduction), drove the stock down 2.33% to $140.03. The decline also coincided with the stock falling below its 50-day moving average.
News2026-11-17-0.8%
Merck announced its first-quarter 2027 dividend payment to shareholders.
News2026-11-13+0.6%
Merck receives EU CHMP positive opinion to expand ENFLONSIA clesrovimab approval to children up to 24 months with severe RSV vulnerability.
News2026-11-10-0.5%
FDA approves Merck's PIMJETMI (pimicotinib) as first oral CSF-1R inhibitor for tenosynovial giant cell tumor.
Upcoming catalysts & outlook
Next earnings
2027-02-02 (est.)
in 75 days
10-Q Filing (est.)
2027-02-03
Medium impact
Thesis shift
Bearish Shift
bearish signal
Risk level
Medium
from change events

Frequently asked questions about MRK

Why did Merck & Co., Inc. (MRK) stock move?

Merck & Co., Inc. (MRK) fell 3.9% on November 18, 2026, closing at $137.78 versus $143.37 the prior session (close-to-close, from daily closes). Merck disclosed discontinuation of nemtabrutinib (MK-1026), an oral BTK inhibitor and centerpiece of its $2.7 billion ArQule acquisition, after an independent Data Monitoring Committee determined risks outweighed benefits in the Phase 3 BELLWAVE-011 trial for blood cancers. The decision to shut down the entire BELLWAVE program, combined with significant insider selling by EVP Richard Deluca (58,185 shares, ~34% stake reduction), drove the stock down 2.33% to $140.03. Source: Business Wire.

How much did MRK stock fall?

MRK lost 3.90% ($5.59) versus the prior close of $143.37, last trading at $137.78 on 1.0× average volume.

When is Merck & Co., Inc.'s next earnings date?

MRK's next earnings report is estimated for 2027-02-02 — about 75 days away.

What is the analyst price target for MRK?

The consensus analyst price target for MRK is $159.45, about 15.7% above the current $137.78. Over the past 90 days, analysts recorded 0 upgrades, 19 maintains, and 0 downgrades.

Is the MRK move company-specific or sector-wide?

BestStocks classifies it as a sector-wide move: the peer group moved a median -2.3% against MRK's -3.9%. MRK ranks top 6 of 7 peers.

How BestStocks tracks MRK

This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for MRK, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 19, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataSEC EDGAR filingsFMP earnings & estimatesCompany news feedsAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.